Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MARIZYME, INC.

(GBSX)
  Report
 SummaryQuotesChartsNewsCompanyFinancials 
Quotes 5-day view   Delayed Quote. Delayed Otc Markets
04/13/2021 04/16/2021 04/19/2021 04/20/2021 04/23/2021 Date
0(c) 0(c) 1.2(c) 2.24(c) 2.15 Last
24 5 2 771 500 1 200 Volume
+86.67% -4.02% Change
More quotes
Financials (USD)
Sales 2019 - - -
Net income 2019 -1,06 M - -
Net cash position 2019 0,00 M - -
P/E ratio 2019 -9,73x
Yield 2019 -
Sales 2020 0,20  - -
Net income 2020 -5,85 M - -
Net cash position 2020 1,58 M - -
P/E ratio 2020 -11,3x
Yield 2020 -
Capitalization 80,5 M 80,5 M -
EV / Sales 2019 -
EV / Sales 2020 447 079 874x
Nbr of Employees 18
Free-Float 68,6%
More Financials
Company
Marizyme, Inc. is focused on commercialization of therapies that addresses the acute care space. The Company focuses on applications for its technologies to dental care, wound healing, thrombosis and other tissue preserving uses. Its products include Krillase and DuraGraft. Krillase, is a medical device for treating chronic wounds. Its Krillase pipeline includes MB101 and MB104. MB101 is being developed as a therapy... 
More about the company
All news about MARIZYME, INC.
04/15MARIZYME  : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESU..
AQ
03/31MARIZYME INC  : Financial Statements and Exhibits (form 8-K)
AQ
03/19MARIZYME INC  : Change in Directors or Principal Officers (form 8-K)
AQ
02/26MARIZYME INC  : Change in Directors or Principal Officers (form 8-K)
AQ
02/26MARIZYME INC  : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
02/04MARIZYME INC  : Change in Directors or Principal Officers (form 8-K)
AQ
02/01MARIZYME INC  : Change in Directors or Principal Officers (form 8-K)
AQ
01/29MARIZYME INC  : Change in Directors or Principal Officers (form 8-K)
AQ
2020MARIZYME, INC.  : Expands Executive Team, Board of Directors
PR
2020MARIZYME INC  : Change in Directors or Principal Officers (form 8-K)
AQ
2020MARIZYME  : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESU..
AQ
2020MARIZYME  : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESU..
AQ
2020MARIZYME INC  : Change in Directors or Principal Officers, Financial Statements ..
AQ
2020MARIZYME INC  : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
2020MARIZYME  : Announces European DuraGraft(R) Registry Results Presented at the Eu..
EQ
More news
News in other languages on MARIZYME, INC.

- No features available -

More news
Chart MARIZYME, INC.
Duration : Period :
Marizyme, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers and Directors
NameTitle
James E. Sapirstein Chairman & Chief Executive Officer
Bruce Harmon Chief Financial Officer
Steven Brooks Chief Medical Officer
Donald Very Executive Vice President-Research & Development
Catherine J. Pachuk Chief Science Officer
Sector and Competitors
1st jan.Capitalization (M$)
MARIZYME, INC.-10.40%80
GILEAD SCIENCES, INC.14.64%82 644
VERTEX PHARMACEUTICALS-8.61%55 900
WUXI APPTEC CO., LTD.4.36%52 943
REGENERON PHARMACEUTICALS4.84%51 076
BIONTECH SE107.25%40 805